secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2026-03-27T23:59:59+00:00
Accession:  0001493152-26-013236
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics Q4 net loss $4.1M; FY net loss $25.6M; CLD-401 IND on track for end-2026
--------------------------------------------------------------------------------

- Q4 net loss $4.1M ($0.57/sh); FY net loss $25.6M ($5.95/sh) vs $23.8M ($35.70/sh) in 2024.
- Cash and restricted cash $5.8M at Dec 31, 2025, down from $9.8M a year ago; raised $6.5M in offering/ATM.
- Partnered with Avance Clinical to initiate CLD-401 first-in-human trial in Australia; plans to file IND by end-2026.
- Presented in situ T-cell engager data at AACR-IO; partnered with Matica Bio for GMP manufacturing of CLD-401.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/0001493152-26-013236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer